Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and /or fever
US10640560B2 · kind B2 · utility
2Cited by
122References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2018 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | May 23, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.